imatinib mesylate has been researched along with Macrophage Activation Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bermejo, F; Bernal-Bello, D; de Ancos-Aracil, C; Farfán-Sedano, AI; Frutos-Pérez, B; García-Bermúdez, V; García-Gil, M; Jaenes-Barrios, B; Morales-Ortega, A; Ruiz-Giardin, JM; San Martín-López, JV; Zapatero-Gaviria, A | 1 |
1 other study(ies) available for imatinib mesylate and Macrophage Activation Syndrome
| Article | Year |
|---|---|
Imatinib might constitute a treatment option for lung involvement in COVID-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Humans; Imatinib Mesylate; Interleukin-6; Macrophage Activation Syndrome; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |